Clinical course of Covid-19 in a cohort of patients with Behcet disease.

ABSTRACT:

Objective

The implications of Covid-19 in patients with Behçet's disease (BD) are unknown. Patients with BD usually take long-term therapy with therapeutic agents that have been tested in Covid-19 patients. We aimed to assess the prevalence of Covid-19 in a cohort of patients with BD and investigate whether those patients with a long-term treatment with colchicine, tumor necrosis factor inhibitors (TNFi) or glucocorticoids are at reduced or increased prevalence of Covid-19 related clinical outcomes.

Methods

A retrospective study was conducted among 244 patients with BD (86.1% females; mean age 43.95±11.11 years). Each participant completed an online questionnaire regarding demographics, medical conditions, dispensed colchicine, TNFi or oral glucocorticoids, Covid-19 infectio

SUBMITTER: Correa-Rodriguez M 

PROVIDER: S-EPMC8712259 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature